The most effective and sustainable way to guarantee countries in the Global South long-term access to sufficient pharmaceutical products in line with the needs of their respective populations is to build up regional production capacities. Due to market dynamics, countries with low purchasing power are often excluded from purchasing high-quality medicine. Many of the urgently needed healthcare products such as vaccines, testing kits or antibiotics are not available – and this precisely in those regions of the world where the disease burden is the highest. Moreover, the drugs and vaccines that can be purchased on the global market by these countries are usually of inferior quality, both in terms of their therapeutic effectiveness and the increased risk of undesirable side effects. In times of health and economic crises, even this access can dry up. As long as the import of high-quality pharmaceutical products cannot be covered by national budgets and as long as the discrepancies in income with the developed world persist, countries of the Global South will have to rely on the support of aid organizations and the supply capabilities of second-rate producers to at least alleviate, if not cover, their need for healthcare products.

In light of this, we support countries in the Global South in their efforts to build up regional production capacities. We identify the most urgent domains for local production and work with our partners to develop project designs that have the greatest possible chance of success, are financially viable and, finally and most importantly, meet the health needs of the respective population. Building an infrastructure of pharmaceutical production from scratch can be challenging. This is why it is paramount for each and every project that we manage to bring to the table the right actors at the right time. We maintain a global network of contacts with institutions, companies and governments, which enables us to find the right architecture for every project. We work closely with the health branches of the United Nations, the World Health Organization, the African Vaccine Manufacturing Initiative, and many others; in short, a consortium of committed communities that have recognized the problem of unequal distribution of pharmaceutical manufacturing capacity and are engaged to addressing it.

The range of projects we pursue covers the entire value chain of pharmaceutical production. From R&D activities to Fill and Finish (F&F), Drug Substance (DS) and the manufacturing of the required starting products, the active pharmaceutical ingredients (API), we pursue a broad field of activity. By strategically aligning the inception and culmination of value creation, we meticulously integrate individual projects into a cohesive framework. This concerted effort aims to liberate countries of the Global South from dependency on imports and reliance on donation-based aid. Thus, our mission aligns with the explicitly stated overarching goal of LMICs around the world to fortify against market uncertainties and failures, fostering a resilient ecosystem built on self-sustenance and reduced external vulnerabilities.